Global Blood Therapeutics is a biotechnology business based in the US. Global Blood Therapeutics shares (GBT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $68.49 – the same closing value as a week prior. Global Blood Therapeutics employs 457 staff and has a trailing 12-month revenue of around $234.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $68.49 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $63.70 |
| 200-day moving average | $38.56 |
| Wall St. target price | $64.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $68.49 from 2022-10-05
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-13) | N/A |
| 1 year (2023-10-13) | N/A |
|---|---|
| 2 years (2022-10-13) | N/A |
| 3 years (2021-10-15) | 124.41% |
| 5 years (2019-10-17) | 38.20% |
| Revenue TTM | $234.9 million |
|---|---|
| Gross profit TTM | $191.4 million |
| Return on assets TTM | -25.18% |
| Return on equity TTM | -148.56% |
| Profit margin | -137.3% |
| Book value | $1.76 |
| Market Capitalization | $4.6 billion |
TTM: trailing 12 months
We're not expecting Global Blood Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Global Blood Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Global Blood Therapeutics's is 0.4634. This would suggest that Global Blood Therapeutics's shares are less volatile than average (for this exchange).
Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.